ClinicalTrials.gg
CompletedNCT02367313SPIRITUSUpdated Jun 1, 2018

A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

A Phase 2 interventional study of Vapendavir and Vapendavir in Asthma, sponsored by Biota Pharmaceuticals, Inc.. Completed at 62 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-06-01.

Sponsored by Biota Pharmaceuticals, Inc. (part of Vaxart) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
455
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
244th of 1,353
455 · median 100
Started
2015
with 82 others
Phase 2
292 of 1,695
22 open now
Registered
978th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 244th largest by enrollment of the 1,353 interventional ones that give a count, is one of 83 that started in 2015, is one of 292 in phase 2, and was the 978th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 protocol is designed to compare two dose levels of Vapendavir versus placebo. The objectives are to obtain safety and efficacy data in moderate to severe asthmatic patients, aged 18 to 75 years at risk of loss of asthma control due to presumptive Human Rhinovirus infection.

Read the detailed description

This is a multicenter trial to be conducted at approximately 60 sites among 6-8 northern hemisphere countries in North America and Central Europe. Sufficient patients will be randomized in order to recruit 150 subjects who are laboratory confirmed for human rhinovirus (HRV) infection. Depending on HRV PCR positivity rates, it is expected that randomization of 250-480 subjects will be required to achieve this number of subjects with HRV infection.

Appropriate asthma subjects will be screened up to 180 days prior to presentation at the study site with symptoms of presumed HRV infection for potential study inclusion on Study Day 1. The study drug treatment period has a duration of 7 days, beginning on Study Day 1. Follow-up study visits to the clinic occur on Study Days 3, 5, 7, 14, 21, and 28 with a telephonic final safety follow-up visit conducted on Study Day 35. Thus, depending on the duration of the screening period, a subject's duration of participation can be estimated to last from approximately 37 days up to 215 days.

03

Conditions studied

  • Asthma

Keywords

  • Symptomatic Human Rhinovirus Infection
  • Moderate to Severe Asthma
  • Antiviral
  • Cold
  • Aviragen Therapeutics, Inc.
  • Aviragen Therapeutics
  • Aviragen
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Moderate and severe male and female asthma subjects aged 18 to 75 years, (inclusive)
  2. Established clinical history of Asthma for at least 1 year, and a history within the last 14 months (prior to screening) of asthma exacerbation due to presumed viral respiratory infections, which required asthma rescue medication treatment.
  3. The asthma subjects will be currently taking at least medium-dose or high-dose ICS defined as fluticasone at a dosage of at least >264 µg daily and may be taking other asthma medication preparations. The asthma subjects' medication regimen must be stable for at least 4 weeks before screening.
  4. Subjects will have at screening or within the last year, documented variable airway obstruction as indicated by an increase in (>12%) to short acting bronchodilator, or positive methacholine challenge, or positive histamine challenge (PC20 \<8 mg/mL).
  5. Upon presentation to the clinic with cold symptoms, subjects will be required to be randomized and treated within 48 hours of symptom onset and will be qualified for presumptive rhinovirus infection by:

    1. clinical exam and the presence of each of the following Day 1 WURSS-21 symptoms at a severity of 2 or greater: runny nose, sore throat, scratchy throat.
    2. subjects must also have a minimum total symptom score on the Day 1 WURSS-21 of 20 points.
    3. subjects will be further qualified as presumptively infected with HRV via exclusion of subjects having significant fever and exclusion of subjects testing positive for influenza via Rapid Antigen Test.

Exclusion criteria

Exclusion Criteria:

  1. Subjects presenting to the clinic with a current severe asthma exacerbation will be excluded from randomization, as well as any subject with an additional underlying respiratory medical condition other than asthma such as , cystic fibrosis, or chronic sinusitis, or any other uncontrolled disease which would interfere with the assessment outcomes or subject safety.
  2. Female subjects must not be pregnant or breastfeeding. Females of must be willing to utilize a double barrier method of , as defined in this protocol, regardless of any hormonal contraception they may be concomitantly receiving.
  3. Male subjects must agree to use a method of birth control defined in this protocol.
  4. The use of medications known to moderately or severely inhibit or induce cytochrome (CYP) 3A4 and 2C19 enzymes, or those known to be sensitive substrates (with a narrow therapeutic range) of these CYPs are restricted.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
455 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Active comparator
    Vapendavir 264 mg

    Vapendavir 264 mg and matching placebo

    Drug: Vapendavir

  • Active comparator
    Vapendavir 528 mg

    Vapendavir 528 mg and matching placebo

    Drug: Vapendavir

Interventions

  • Vapendavir 264 mg twice daily

    Also known as: BTA798

  • Vapendavir 528 mg twice daily

    Also known as: BTA798

  • DrugPlacebo

    Placebo twice daily

06

What researchers measure

Primary outcomes

  1. Asthma Control Questionnaire-6 (ACQ-6)

    Least Square (LS) mean change from baseline (Day 1) to Study Day 14 in ACQ-6 total score

    Time frame: Baseline (Day 1) to Study Day 14

07

Study locations

62 sites
  • Biota Investigational site
    Birmingham, Alabama 35209, United States
  • Biota Investigational site
    Flagstaff, Arizona 86001, United States
  • Biota Investigational site
    Bakersfield, California 93301, United States
  • Biota Investigational site
    Los Angeles, California 90025, United States
  • Biota Investigational site
    Orange, California 92868, United States
  • Biota Investigational Site
    San Jose, California 95117, United States
  • Biota Investigational site
    Stockton, California 95207, United States
  • Biota Investigational site
    Centennial, Colorado 80112, United States
  • Biota Investigational site
    Denver, Colorado 80230, United States
  • Biota Investigational site
    Hialeah, Florida 33016, United States
  • Biota Investigational site
    New Port Richey, Florida 34653, United States
  • Biota Investigational site
    Oviedo, Florida 32765, United States
  • Biota Investigation site
    Palmetto Bay, Florida 33157, United States
  • Biota Investigational site
    Tallahassee, Florida 32308, United States
  • Biota Investigational site
    Twin Falls, Idaho 83301, United States
  • Biota Investigational site
    Baltimore, Maryland 21236, United States
  • Biota Investigational site
    Saint Louis, Missouri 63141, United States
  • Biota Investigational site
    Bellevue, Nebraska 68123, United States
  • Biota investigational site
    Las Vegas, Nevada 89146, United States
  • Biota Investigational site
    Ocean City, New Jersey 07712, United States
  • Biota Investigational site
    Albuquerque, New Mexico 87102, United States
  • Biota Investigational site
    Rockville Centre, New York 11570, United States
  • Biota Investigational site
    Raleigh, North Carolina 27607, United States
  • Biota Investigational site
    Fargo, North Dakota 58103, United States
  • Biota Investigational site
    Middleburg, Ohio 44310, United States
  • Biota Investigational site
    Toledo, Ohio 43617, United States
  • Biota Investigation site
    Oklahoma City, Oklahoma 73120, United States
  • Biota Investigational site
    Medford, Oregon 97504, United States
  • Biota Investigational site
    Portland, Oregon 97202, United States
  • Biota Investigational site
    Warwick, Rhode Island 02886, United States
  • Biota Investigational site
    Houston, Texas 77055, United States
  • Biota Investigational site
    Seattle, Washington 98115, United States
  • Biota Investigational site
    Greenfield, Wisconsin 53228, United States
  • Biota Investigational site
    Ruse, 7002, Bulgaria
  • Biota Investigational site
    Sofia, 1202, Bulgaria
  • Biota Investigational site
    Sofia, 1407, Bulgaria
  • Biota Investigational site
    Sofia, 1606, Bulgaria
  • Biota Investigational site
    Sofia, 1618, Bulgaria
  • Biota Investigational site
    Stara Zagora, 6000, Bulgaria
  • Biota Investigational site
    Jindrichuv Hradec, 37701, Czechia
  • Biota Investigational site
    Kyjov, 69733, Czechia
  • Biota Investigational site
    Lovosice, 41002, Czechia
  • Biota Investigational site
    Melnik, 27601, Czechia
  • Biota Investigational site
    Prague, 18200, Czechia
  • Biota Investigational site
    Rokycany, 33722, Czechia
  • Biota Investigational site
    Tbilisi, 0102, Georgia
  • Biota Investigational site
    Tbilisi, 0159, Georgia
  • Biota Investigational site
    Tbilisi, 0186, Georgia
  • Biota Investigational site
    Bialystok, 15-044, Poland
  • Biota Investigational site
    Kielce, 25-734, Poland
  • Biota Investigational site
    Krakow, 31-023, Poland
  • Biota Investigational site
    Lodz, 90-153, Poland
  • Biota Investigational site
    Lublin, 20-552, Poland
  • Biota Investigational site
    Skierniewice, 96-100, Poland
  • Biota Investigational site
    Warsaw, 01-868, Poland
  • Biota Investigational site
    Wroclaw, 50-044, Poland
  • Biota Investigational site
    Wroclaw, 51-162, Poland
  • Biota Investigational site
    Brasov, 500112, Romania
  • Biota Investigational site
    Bucharest, 020671, Romania
  • Biota Investigational site
    Craiova, 200446, Romania
  • Biota Investigational site
    Mures, 547530, Romania
  • Biota Investigational site
    Sibiu, 550360, Romania
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2015
First posted
Feb 20, 2015
Start
Feb 2015
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results delay requested
Mar 17, 2017
Last update
Jun 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02367313
Responsible party
Sponsor
First posted
Feb 20, 2015
Start date
Feb 2015
Primary completion
Dec 2016
Completion
Dec 2016
Last update
Jun 1, 2018

Study contacts

Anna Novotney-Barry
study director · Biota Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vapendavir

Start the discussion